Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy

2024-01-08

免疫疗法临床1期疫苗

MISSOULA, Mont. and NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical-stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration. Intrommune is advancing a clinical stage oral mucosal therapy for food allergies in allergic individuals. This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its peanut oral mucosal immunotherapy (OMIT), with the rapid desensitization to allergens provided by Inimmune’s clinical stage proprietary immunotherapy. The combination of these two approaches is expected to result in the rapid and long-term relief of allergic symptoms resulting from peanut exposure and would be a game changer for patients suffering with this potentially life-threatening allergy.

“The combination provides an opportunity to significantly advance the prevention of allergic symptoms related to exposure to peanut allergen in susceptible individuals. The combination of technologies provided by each company can completely change the treatment paradigm associated with serious food related allergic reactions,” said Alan Joslyn, Ph.D., Inimmune’s CEO. “We look forward to advancing the combined technologies into the clinic in the near future.”

The two companies plan to work together to evaluate the potential for combining the two clinical stage immunotherapies.

Oral mucosal immunotherapy utilizes complex patented biochemical processes to stabilize and deliver allergenic proteins in a fully functional toothpaste. Through the act of tooth brushing, the allergenic proteins can be delivered to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization.

“This collaborative opportunity between Intrommune and Inimmune represents a significant step forward in the fight to reduce the physical and psychological burden that food allergies have on millions of individuals living with food allergy,” said Michael Nelson, Intrommune’s founder and CEO. “By combining our disease-modifying, patient-friendly treatment platform with Inimmune’s proprietary rapid desensitization technology, we look to create a future free from the fear of food allergies.”

About Intrommune Therapeutics

Intrommune (New York, NY), dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary Oral Mucosal Immunotherapy (OMIT) treatment platform for food allergies. OMIT is a patient-friendly solution for over 220 million people worldwide, including 33 million people in the United States, who suffer from life-altering food allergies. Intrommune Therapeutic’s lead product, INT301, has completed its Phase 1 clinical trial. All Phase 1 results along with future studies are intended to support OMIT as being a safe, effective and convenient therapy for patients who suffer from peanut allergy.

For more information on Intrommune’s research and development approaches to treating significant allergies and delivery systems, please visit www.intrommune.com.

About Inimmune Corporation

Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics, vaccine adjuvants, and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity, and cancer. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula.

For more information on Inimmune's research and development of novel vaccine adjuvants, immunotherapeutics and delivery systems, please visit www.inimmune.com.

Contact:

Media Relations

Inimmune Corporation

Phone: (406)-541-5913

Email: info@inimmune.com

Contact:

Stuart Loesch

Intrommune Therapeutics

Phone: (484) 942-0323

Email: sloesch@intrommune.com

Cautionary Statement Regarding Forward Looking Statements

This release may contain "forward-looking statements." Forward-looking statements are identified by certain words or phrases such as "may," "will," "aim," "will likely result," "believe," "expect," "will continue," "anticipate," "estimate," "intend," "plan," "contemplate," "seek to," "future," "objective," "goal," "project," "should," "will pursue" and similar expressions or variations of such expressions. These forward-looking statements reflect Intrommune’s and Inimmune’s current expectations about their respective future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement. Intrommune and Inimmune disclaim any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

This release does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States or in any other jurisdiction.